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Abstract
Background -: Data on clinical presentation, morbidity and mortality of 2009 pandemic influenza virus (H1N1v) in
paediatric population are still emerging; most of the data so far available came from selected cohorts of children
admitted to tertiary care paediatric hospitals.
Methods -: An observational study involving all the 19 Divisions of Paediatrics of the Veneto Region was
conducted with the aim of investigating into the demographic and clinical characteristics, the treatment, the
outcome and the risk factors for disease severity of H1N1v infection occurring in children.
Results -: Two hundred children, median age of 4.15 years (range 0-15) were enrolled from the last week of
October till the first week of January 2010 for an overall hospitalization rate of 23/100.000. At least one underlying
medical condition was found in 44% of patients. Fever and cough were the most frequent symptoms (93% and
65% respectively). 11 patients (6%) were admitted to a PICU and 5 (2.5%) required mechanical ventilation. Antiviral
therapy was administered in 103 patients (51.5%) Death occurred in 2 patients (1%); both had severe prior medical
conditions. Pre-existing neurologic diseases (OR 7.82; 95%CI: 1.15-53.34), the presence of hypoxemia (OR 10.47; 95%
CI: 2.12-51.70) and anemia (Haemoglobin < 10 g/dL) (OR 14.15; 95%CI: 2.36-84.64) were risk factor for Intensive
Care Unit admission.
Conclusions -: This observational study in a given area of North-East Italy confirms the rather favourable prognosis
of children with influenza A H1N1 (2009). Pre-existing conditions, and which is new, significant anemia, are risk
factors for a complicated course.
Introduction
Compared to seasonal influenza, H1N1 2009 pandemic
influenza virus (H1N1v) had an increased infection rate
among children and adolescents [1-3]. Even though the
illness has been mostly acute and self limited, a variable
spectrum of disease severity has been reported from
mild illness to death. Children with underlying chronic
disease are at increased risk for complications and death
from influenza [4-10].
However, data on clinical presentation, morbidity and
mortality of novel influenza A H1N1v in paediatric
population are still emerging. In fact, during weeks 49
to 52 of 2010, influenza activity in the Northern Hemi-
sphere still increased, in particular in Europe, with A
(H1N1) and B viruses predominating [11]. The United
Kingdom (U.K.) continues to report high rates of influ-
enza. As February of 2011 approximately 25% of inten-
sive care beds are occupied by influenza cases and 112
influenza-related deaths have been reported. 95 of 100
fatal cases from which the virus has been sub-typed
have been H1N1 (2009) related and the other 5, influ-
enza type B. The majority of severe and fatal cases have
been between adolescent and adult population [11].
For all of these facts it is important to collect and criti-
cally analyze clinical information that may be useful for
the correct management of patients in the near future.
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those that exist are usually cohorts of children in ter-
tiary care hospital [4,12-16], thus not describing the
actual severity of illness in all children admitted to any
hospital.
The first cases of confirmed infection with the H1N1v
virus in Italy were documented in Autumn 2009. By
October 2010, 5.582.000 illnesses, 938 hospitalizations
(455 in Intensive Care Units, ICU) and 228 deaths were
estimated in Italy [17]. In order to investigate the demo-
graphic and clinical characteristics, the treatment and
the outcome of a large cohort of Italian children hospi-
talized because of the H1N1v Infection, we conducted
an observational study in the Veneto region, a geo-
graphic area located in the North-East of Italy. The cur-
rent study is also aimed to look into the risk factors for
disease severity.
Patients and Methods
In Italy there is a system of seasonal flu epidemic sur-
veillance, Influnet. Family doctors and paediatricians,
called “sentinel physicians”, representing all Italian
Regions, insert the influenza cases observed during the
epidemic season in a website. They share a common
operative protocol. Every week the National Institute of
Health makes provision to process data [17].
Geographic setting
The study was a retrospective observational study invol-
ving all the 19 Divisions of Paediatrics of the Veneto
Region, included two Paediatric Tertiary care centres
with their own Paediatric Intensive Care Units (PICU).
This area has a population of 867.521 subjects aged less
than 15 years of age, representing 19% of all inhabitants.
Inclusion criteria
Eligible patients were all children under 15 years of age
hospitalized in paediatric wards for H1N1v infection
documented by testing combined nasal and throat
swabs. All samples were sent to the Microbiology and
Virology Division of the University Hospital of Padua
for the research of H1N1v virus using reverse-transcrip-
tase Real-Time polymerase-chain-reaction assay (RT-
PCR) [18]. When required, the neuroaminidase (NA)
gene of the viral isolates was also sequenced, by auto-
mated Applied Biosystems sequanator. Data collection
started since the first week in which the virus was
detected (October 2009) in a hospitalized child and
extended through the last week the virus was detected
(January 2010).
Data collection
Demographic and clinical data for each study patient were
collected using a standardized data collection form that
included demographic information, influenza vaccination
history, underlying medical conditions, clinical signs and
symptoms, selected laboratory tests, radiographic findings,
therapy, treatment course, complications and outcome in
terms of duration of hospitalization, need for PICU, dis-
charge or death.
All information was sent to the data-collection centre
in Padua where a computerized database was created.
The study was approved by the Research Ethics Com-
mittee of Padua Hospital and of the participating
centres.
Statistical analysis
Continuous variables were expressed as median and
interquartile range (IQR) due to the non-parametric
distribution; categorical variables were expressed as
percentages. Comparison for continuous variables was
performed by means of Mann Whitney U test for non-
normally distributed data. For categorical data, the X2
test with Yates correction for 2 × 2 tables was used.
We used p < 0.05 as a threshold for statistical
significance.
A multiple logistic regression model was used to
identify variables independently associated with the
outcome variable, namely admission to PICU. A step-
wise regression procedure was used in obtaining the
final model.
Results
Two-hundred eligible children were enrolled during
the study period. Fifty-seven (28.5%) were hospitalized
in tertiary care centres. In the Veneto region the regis-
tered hospitalization for H1N1v influenza started in
the last week of October with a peak in November
2009 and terminated in the first week of January 2010
a tt h et i m eo ft h el a s tr e p o r t e dc a s e( F i g u r e1 ) .T h e
overall hospitalization rate was 23/100.000 children
(age less than 15 years) and, more precisely, 20/
1 0 0 . 0 0 0i nc h i l d r e nl e s st h a n2y e a r so fa g e ,4 0 /
100.000 in those aged 2 to 5 years and 27/100.000 in
the older ones.
Epidemiological and clinical characteristics
The epidemiological characteristics and the pre-existing
conditions of the children of the cohort we studied are
reported in table 1. The median age was 4.15 years with
a slight male predominance; most of the children were
Caucasian. Seventy-nine children (40%) had one or
more pre-existing medical conditions, including chronic
lung diseases (14%) and asthma (13%), hemoglobinopa-
t h i e s( 1 4 % ) ,h e a r td i s e a s e s( 9 % ) ,n e u r o l o g i cd i s o r d e r s
(28%), cancer (6%) and immunodeficiency (6%). Obesity
was not represented in our sample as an underlying
condition. The percentage of children suffering from
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and 27% in the remaining institutions. Three patients
had received the H1N1v vaccine while seven the seaso-
nal influenza vaccine.
The median time from onset of symptoms to hospita-
lization was 1.3 days (range 0.5-4). Fever and cough
were the two most frequent symptoms at admission
(93% and 65% respectively - Table 2). Dyspnoea and
wheezing were noted in 30% and 15.5% of the children
respectively. Hypoxemia (sat 02 < 93%) at admission
was present in 34 patients (17%). Gastrointestinal symp-
toms, such as vomiting (17.5%), diarrhoea (5%) or
abdominal pain (5%) were also reported as well as aspe-
cific symptoms such as fatigue and myalgia.
Laboratory and instrumental findings
The laboratory and instrumental findings which were
investigated are reported in Table 2.
Chest radiographs were suggestive of pneumonia in
104 patients, in most cases (76%) they showed lobar
consolidation, unilateral or bilateral. In five cases pneu-
monia were associated with pleural effusion.
Laboratory confirmed co-infections were documented
in nine children: four had a positive blood culture,
respectively for Candida glabrata, Streptoccocus agalac-
tiae, Neisseria meningitidis,a n dStaphylococcus aureus
and 5 cases a positive serological test for recent Myco-
plasma pneumoniae infection.
Treatment
Antiviral therapy was administered in 103 patients
(51.5%) after a median of 3 days (IQR 2-5) from the
Figure 1 Epidemiologic curve of hospitalization H1N1v virus infection (October 2009 and January 2010).
Table 1 Demographic features and pre-existing
conditions of the study population
Demographic characteristics
Age (years)
Median 4.15
Range 0.8-7.5
Age groups (years): N° of patients (%)
<2 73 (37)
2-5 42 (21)
5-18 85 (42)
Male sex, N° (%) 114 (57)
Race, N° (%)
Caucasian 156 (78)
African 29 (14.5)
Asian 8 (4)
Others 7 (3.5)
Pre-existing conditions, N°. (%) 79/200 (40)
Type of pre-existing conditions N°
Chronic lung disease 11/79 (14)
Asthma 10/79 (13)
Hemoglobinopathy 11/79 (14)
Heart disease 7/79 (9)
Neurological disease 22/79 (28)
Cancer 5/79 (6)
Immunosuppression 5/79 (6)
Other 8/79 (10)
Vaccination status
H1N1 vaccine, N° (%) 3 (2)
Seasonal influenza vaccine, N° (%) 7 (4)
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therapy within 48 hours of the onset of symptoms. One-
hundred-and-one children were treated with Oseltamivir
and 2 with Zanamivir. In one case nebulized Zanamivir
aqueous solution was administred for development of
H1N1v viral mutation (H275Y), at the level of the NA
gene, which conferred resistance to the initial treatment
with Oseltamivir. The median duration of antiviral ther-
apy was 4 days (IQR 4-5 days). Antiviral therapy was
administered more frequently in patients with chronic
diseases compared to healthy subjects (73% Vs. 37%, p <
0.0001) which explains why such therapy was adminis-
tered more frequently in tertiary care centers compared
with other pediatric institutions (84% versus 38%).
Outcomes
Eleven patients (5.5%), ten with a pre-existing clinical
conditions, were admitted to PICU; 6 (3%) required
mechanical ventilation for a median duration of 7 days
(IQR 3.75-26.5) and 1 extracorporeal membrane oxyge-
nation (ECMO). The median age of patients admitted to
PICU was 3.8 years (IQR 2.4-4.6). The median length of
hospital stay was 4 days (IQR 3-6.5) while the median
length of stay in ICU was 6.5 days (IQR 4-8).
Two children with severe pre-existing clinical condi-
tions died (1%); one, a 3-year old girl affected by a com-
plex congenital heart disease, died of combined
respiratory and cardiac failure despite 10 days therapy
with Oseltamivir and aggressive respiratory support
including ECMO. The other patient, also a 3-year old
girl, affected by Niemann Pick disease and suffering of
an important hepatosplenomegaly, died of respiratory
failure and superimposed Staphylococcus bacteraemia
after 73 days of hospitalization.
As we can see on bivariate analysis (Table 3), that
compared patients admitted to the PICU to those hospi-
talized in regular ward, clinical factors that resulted sig-
n i f i c a n t l ym o r er e p r e s e n t e di nt h ef i r s tg r o u po f
children were: pre-existing clinical conditions and
among them, neurological diseases, wheezing, dyspnoea,
hypoxemia and a haemoglobin level less than 10 g/dL.
Multivariate logistic-regression analysis showed that
the following were independent risk factors for admis-
sion to the ICU: pre-existing neurologic diseases (OR
7.82; 95%CI: 1.15 to 53.34), the presence at admission of
hypoxemia (OR 10.47; 95%CI: 2.12 to 51.70) and anemia
(Haemoglobin < 10 g/dL) (OR 14.15; 95%CI: 2.36 to
84.64).
Discussion
This series of hospitalized children infected with the
influenza A H1N1v virus, one of the largest so far pub-
lished, provides complementary data about the natural
history and the clinical management of this disease in
children, to the amount of information provided in such
a short period of time since the first case documented
on April 2009[19]. It includes patients all belonging to a
well-defined area (the Veneto Region) and involves all
paediatric institutions of any level. The hospitalization
rate for children with influenza A H1N1v virus we
documented, was equal to 23/100.000 with a peak in
those aged between 2 and 5 years. It is difficult to com-
pare these figures with the data available in the litera-
ture. In a series from California the hospitalization rate
for all age groups was 2.8/100.000 ranging from 35.8/
100.000 in infants 1 month old to 1.5/100.000 in
patients aged 70 or older [7]. In the Argentina study,
the corresponding figure was 20/100.000 in children less
than 18 years [4]. Probably, differences in data collection
Table 2 Clinical, laboratory and instrumental findings of
the study population
Clinical signs and symptoms, N° (%)
Fever 185 (93)
Cough 129 (65)
Dyspnoea 60 (30)
Wheezing 31 (15.5)
Chest pain 6 (3)
Rhinorrhea 69 (35)
Asthenia 98 (49)
Myalgia 7 (4)
Abdominal pain 11 (5)
Vomiting 35 (17.5)
Diarrhoea 10 (5)
Rash 3 (2)
Headache 2 (1)
Hypoxemia (sat 02 <93%), N° (%) 34 (17)
Laboratory Findings
Leukocyte count (mm
3) - median (range) 8480 (5447-11987)
Neutrophils (%) - median (range) 64 (39-77)
Haemoglobin (g/dl) - median (range) 11.9 (10.8-13.1)
Haemoglobin < 10 g/dL, N° (%) 28 (14.4)
Platelet count per mm
3-median (range) 268.000 (201.500-355.000)
PCR (mg/l) - median (range) 8.1 (2.3-26.8)
Procalcitonin (μg/L) - median (range)
Positive blood culture*- patients N° 4
Elevated aspartate aminotransferease, N° 7
Chest Radiography
Pneumonia - N°/total N° (%) 107/132 (81.1)
Interstitial pneumonia, N° (%) 25 (24)
Lobar consolidation 79 (73.8)
Unilateral consolidation, N° (%) 44 (41.1)
Bilateral consolidation, N° (%) 20 (18.6)
Pleural effusion, N° (%) 5 (4)
*S. aureus, Candida glabrata, S. agalactiae, N. meningitidis
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in the potential different clinical behaviour of the dis-
ease should be accounted to explain this geographic dif-
ference in the hospitalization rate. Certainly, influenza A
H1N1v virus has affected more patients than seasonal
influenza in a short time span worldwide [1]. Also in
Italy, during the peak period in November 2009, the
incidence of the H1N1v virus infection was 12.92/1000
compared to 8.23/1000 for 2007-2008 seasonal influenza
in the same population [16].
In our series the median age of those children who
were hospitalized was 4 years, a finding which is com-
parable to what most of series have so far reported
[6,7,11,12,14,15,20]. Only the group from Argentina
Table 3 Comparison between clinical characteristics of children admitted to the Intensive Care Unit and to the regular
ward
Variable Admitted to ICU (11 pts) Admitted to regular ward (189 pts) P
Age in years (range) 3.8 (2.4-4.6) 4.3 (0.7-7.6) 0.834
Sex, M/F 7/4 107/82 0.885
Pre-existing condition N° (%) 10 (90.9) 69 (36.5) 0.0011
Asthma 0/11 10/189 0.94
Other chronic lung disease 0/11 11/189 0.88
Hemoglobinopathy 1/11 10/189 0.88
Heart disease 2/11 5/189 0.06
Neurologic disease 5/11 17/189 0.0011
Cancer 0/11 5/189 0.65
Immunosuppression 0/11 5/189 0.65
Other 2/11 6/189 0.09
Clinical signs and symptoms, N° (%)
Fever 10 (91) 175 (92.6) 0.702
Cough 7 (63.6) 122 (64.5) 0.793
Dispnea 8 (72.7) 52 (27.5) 0.0045
Wheezing 5 (45.5) 26 (13.7) 0.0166
Hypoxemia at admission (Sat O2 <93%) 8 (72.7) 26 (13.7) <0.0001
Chest pain 0 6 (3.2) 0.757
Rhinorrea 4 (36.4%) 65 (34.4) 0.847
Asthenia 6 (54.5%) 92 (48.6) 0.946
Myalgia 0 7 (3.7) 0.846
Abdominal Pain 0 11 (5.8) 0.886
Vomiting 3 (27.3%) 32 (17) 0.638
Diarrhea 0 10 (5.3) 0.940
Laboratory Results (range)
Leukocyte–per mmc 5700 (4700-8380) 8600 (5590-12075) 0.1186
Neutrophils–per mmc 73 (47-77) 64 (39-77) 0.607
CRP–mg/L 28.5 (3-64) 7 (2.2-25.7) 0.137
Hb–g/dL 9.8 (8.4-11.1) 12 (11-13.2) 0.001
Hb < 10 g/dL, N° (%) 5/11 (45) 23/189 (12) 0.0046
Chest Radiograph (132 patients)
Abnormal Chest X-rays, N° (%) 11/11 (100) 96/121 (79.3) 0.203
Interstitial/focal consolidation, N° 2/9 23/70 0.9143
Unilateral/Bilateral consolidation, N° 4/5 55/15 0.0752
Pleural effusion, N° (%) 1/11(9) 4/121 (3.3) NS
Therapy
Antiviral treatment, N° (%) 9 (81) 94 (50) 0.078
Days from onset of symptoms to initiation 5 (2-6.75) 3 (1.75-5) 0.203
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who were hospitalized [4].
In the present series, the prevalence of children
affected by pre-existing chronic conditions was relatively
l o w-3 9 %-i nc o m p a r i s o nw i t ho t h e rs e r i e sw h i c h
report values as high as 80% [6,7,10,12,15]. These pre-
existing conditions were, in order of frequency: chronic
pulmonary diseases, haemoglobinopathies and neurolo-
gical disorders. The fact that this is an unselected series
accounting also for those children admitted to non ter-
tiary care centres, thus less likely to be suffering of
chronic conditions, could be accounted for explaining
the low prevalence of predisposing conditions we docu-
mented in our study population. In this study in fact the
proportion of patients affected by chronic diseases was
significantly higher in third level centers compared with
the other provincial and local hospitals (70.2% Vs 27.3%,
p < 0.0001). Furthermore, the low incidence in this
study of cases of chronic asthma, obesity, clinical condi-
tions which have been counted as a pre-existing condi-
tions and highly represented in the series from America
has contributed to this discordance [4,5]. Reading these
data from a different point of view, the fact that slightly
more than 60% of the children of this series were in a
previous healthy status, underlines the potential severe
clinical course which the disease may have in every chil-
dren. In this regard it is worth highlighting the fact that
one of the child of our cohort of young patients who
ended-up in the PICU, was in a previously healthy
status.
Despite these differences, the clinical, laboratory and
radiographic manifestations of the H1N1v infection in
this series were comparable to the ones reported by
other studies.
As just said and described, the course of the H1N1v
virus infection, despite generally very favourable, could
be quite severe with even possible fatal outcomes.
Severe pneumonia with respiratory distress syndrome,
resulting in PICU admission, is the most common
severe complication potentially bringing to death
[4,5,9,10].
In this series only 5.5% of hospitalized children were
admitted to PICU, rate which goes up to almost 20% if
we considered only those children admitted to tertiary
care centres. In terms of PICU admission rate these fig-
ures are surprisingly equal to the ones produced by the
other paediatric series [4,6,14].
It is universally accepted that the presence of pre-
existing conditions mainly neurological and cardiac dis-
orders and asthma, are associated with a higher rate of
admission to the PICU and death [4,7,9,11,12,14,15]. In
this regard it is worth noticing that none of our patients
who ended up in the PICU were affected by asthma.
This is a remarkable difference from other series which
report incidences of asthma among the pre-existing con-
ditions leading children to the PICU up to 85%.
The high quality of asthma control within the general
population could be one of the reason why we did not
document this detrimental effect of asthma on the dis-
ease outcome [21]. In our cohort also anemia and
hypoxemia resulted significant predictors of higher ICU
admission rate. The rate of fatal outcomes in the cohort
of children we studied is in the low range of the rates
so far reported which varies from 1 to 5% [4,6,7,12,15].
Young age (less than 1 year) has been claimed as a risk
factor for fatal outcome but the data has not been con-
firmed by our series as well as by others [4,6].
The impact of therapy and of an early intervention on
the outcome of the infection has been extensively dis-
cussed in the different reports [22,23]. Half of the
patients of this series were treated with neuroaminidase
inhibitors including all the ones admitted to the PICU.
At that time the principles which guided virus directed
therapy were the following: to treat all children at risk;
neonates and young infants, to rely on the clinical jud-
gement for starting therapy in previously healthy chil-
dren with uncomplicated diseases and ideally, to
prolong treatment until complete virus clearance. How-
ever, from all the data so far produced no firm conclu-
sions can be drawn on the role of this therapy and of an
early intervention in reducing the length of hospital stay
and/or the severity of the disease. The two patients of
the present series who died were both affected by a
sever pre-existing condition after having being treated
for 10 and 73 days respectively with the appropriate
therapy. Except for these two fatal outcomes, all other
children had a full recovery which underlines once again
the excellent prognosis of this viral infection.
It is worth mentioning the development, in a 3-year
old severely immunocompromised patient, of resistance
to oseltamivir, due to the appearance of H275Y muta-
tion in the neuraminidase gene. A subsequent treatment
with zanamivir was then able to clear the virus.
T h em a i nl i m i t so ft h i ss t u d yw e r ei nt h em a n n e ro f
data acquisition, since the collection was obtained by
different clinicians, eventhough a uniformed report form
was used and a good standardization of care exists in
t h eV e n e t oR e g i o na n dt h ef a c tt h a ti tr e l i e so nc h a r t
review.
Conclusions
In summary, this quite large series of Italian children
infected by the influenza A H1N1v virus collected by
pulling together the epidemiological and clinical infor-
mation coming from the various paediatric divisions of
the Veneto region confirms that the prognosis is quite
favorable for 11 previously healthy children hospitalized
with influenza H1N1. However, serious complication
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disease burden is high.
These conclusions appear to be relevant especially
considering that we are likely to face a new wave of
H1N1v infection and data guiding towards the best
management of patients are required.
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